Coverage for costs associated with reading of amyloid PET images from PARIS study

承保与读取 PARIS 研究中的淀粉样蛋白 PET 图像相关的费用

• 批准号: 10013900
• 负责人: Tim West
• 金额: $ 25万
• 依托单位: C2N DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-15 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10013900
• 关键词: Administrative Supplement; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Amyloid; Amyloid beta-Protein; Autopsy; Award; Biological Assay; Blood; Brain; Brain Pathology; Clinical; Clinical Research; Data; Development; Diagnostic; Diagnostic tests; Human; Image; International; Laboratories; Mass Spectrum Analysis; Neurofibrillary Tangles; Parents; Plasma; Positron-Emission Tomography; Reader; Reading; Sampling; Senile Plaques; Site; Small Business Innovation Research Grant; Technology; Testing; Time Study; Training; Universities; Washington; base; cerebral amyloidosis; cost; diagnostic assay; imaging agent; instrumentation; meetings; news; patient subsets; predictive test; radiologist; symposium; tau Proteins

PROJECT SUMMARY FOR PARENT AWARD For a long time, the study of Alzheimer’s disease (AD) in humans has been hampered by the fact that absolute AD diagnosis could only be ascertained by assessment of brain pathology upon autopsy. More recently, imaging agents have become available that allow direct imaging of the two hallmarks of AD (amyloid plaques and tau tangles) in living humans. However, these imaging agents are expensive and invasive for use in routine diagnostics. The need for low-cost blood based diagnostic assays has never been greater. C2N Diagnostics has been developing mass spectrometry-based assays that investigate amyloid beta peptides in biofluids since 2007. Recent advances in sample cleanup, purification of amyloid beta, and mass spectrometry instrumentation have made it possible to reliably quantify amyloid beta in human plasma samples. Preliminary data from Dr. Randall Bateman’s laboratory at Washington University shows that the ratio of two amyloid beta peptides in plasma can predict the presence of amyloid plaques in the brain. This technology could revolutionize the field of AD diagnostics, and when presented at the Alzheimer’s Association International Conference in July 2017, this discovery was pronounced as “by far the biggest news of the meeting” by one of the key opinion leaders in AD clinical research. The specific aims of this SBIR Fast- Track application are to analytically and clinically validate C2N’s plasma assay for use as a diagnostic test for predicting brain amyloidosis.

家长奖项目总结

项目成果

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.

临床％20验证％20的％20the％20PrecivityAD2％20blood％20测试：％20A％20mass％20基于光谱的％20测试％20与％20算法％20组合％20％p-tau217％20和％20Aβ42/40％20比率％20到％20识别％20存在

• DOI: 10.1002/alz.13764
• 发表时间: 2024
• 期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
• 作者: Meyer,MatthewR;Kirmess,KristopherM;Eastwood,Stephanie;Wente-Roth,TraciL;Irvin,Faith;Holubasch,MaryS;Venkatesh,Venky;Fogelman,Ilana;Monane,Mark;Hanna,Lucy;Rabinovici,GilD;Siegel,BarryA;Whitmer,RachelA;Apgar,Charles;Batema
• 通讯作者: Batema

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.

• DOI: 10.1001/jamanetworkopen.2022.8392
• 发表时间: 2022-04-01
• 期刊: JAMA network open
• 影响因子: 13.8
• 作者: Hu Y;Kirmess KM;Meyer MR;Rabinovici GD;Gatsonis C;Siegel BA;Whitmer RA;Apgar C;Hanna L;Kanekiyo M;Kaplow J;Koyama A;Verbel D;Holubasch MS;Knapik SS;Connor J;Contois JH;Jackson EN;Harpstrite SE;Bateman RJ;Holtzman DM;Verghese PB;Fogelman I;Braunstein JB;Yarasheski KE;West T
• 通讯作者: West T